Mulpleo (previously Lusutrombopag Shionogi) (lusutrombopag)
- Region
- 🇪🇺 EU
- Active substance
- lusutrombopag
- Company
- Shionogi B.V.
- Status
- Withdrawn
- Therapeutic area
- Thrombocytopenia
- CHMP opinion
- Thu 13 Dec 2018
- EU approval
- Mon 18 Feb 2019
- Application
- EMEA/H/C/004720
- ATC
- B02BX
- Official record
- www.ema.europa.eu
Indication
Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
Regulatory milestones
No milestones recorded in the last year.
Follow Mulpleo (previously Lusutrombopag Shionogi)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.